SuperworthChampions Oncology revenue CSBR
Sales by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jul 31, 2026
- $60.7M
- Latest quarter, Q1 FY27
- $15.2M
- +9% on a year earlier
- Fiscal year 2026
- $59.4M
- +4% on the year before
Champions Oncology's revenue was $60.7M over the twelve months to Jul 31, 2026, up 7% on a year earlier.
In its latest quarter, Q1 FY27, it was $15.2M, up 9% on the same quarter a year before.
Over the five fiscal years to FY2026 it grew 8% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2026 | $59.4M | +4% |
| FY2025 | $56.9M | +14% |
| FY2024 | $50.2M | −7% |
| FY2023 | $53.9M | +10% |
| FY2022 | $49.1M | +20% |
| FY2021 | $41M | +28% |
| FY2020 | $32.1M | +19% |
| FY2019 | $27.1M | +34% |
| FY2018 | $20.2M | +31% |
| FY2017 | $15.4M | +38% |
| FY2016 | $11.2M | +26% |
| FY2015 | $8.9M | −23% |
| FY2014 | $11.6M | +39% |
| FY2013 | $8.3M | +16% |
| FY2012 | $7.2M | +4% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | $15.2M | +9% | $60.7M | |
| Q4 FY26 | $13.8M | +12% | $59.4M | |
| Q3 FY26 | $16.6M | −3% | $57.9M | |
| Q2 FY26 | $15M | +11% | $58.4M | |
| Q1 FY26 | $14M | −0% | $56.9M | |
| Q4 FY25 | $12.4M | −12% | $56.9M | |
| Q3 FY25 | $17M | +42% | $58.6M | |
| Q2 FY25 | $13.5M | +17% | $53.6M | |
| Q1 FY25 | $14.1M | +12% | $51.7M | |
| Q4 FY24 | $14M | +7% | $50.2M | |
| Q3 FY24 | $12M | −6% | $49.2M | |
| Q2 FY24 | $11.6M | −19% | $50M |
Against its peers
Companies in Healthcare nearest Champions Oncology's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| CSBRChampions Oncology | $60.7M | +7% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| APTAlpha Pro Tech | $61.9M | +6% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| ICCCImmucell | $30.7M | +8% a year |
| KEQUKewaunee Scientific | $277.2M | +5% a year |
| NEPHNephros | $20.7M | +24% a year |
| PDEXPro DEX | $77.5M | +16% a year |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| Peer median | $77.5M |
Where Champions Oncology ranks
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Champions Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.